-
Uncategorized1 month agoSTAT+: Capsida says it still doesn’t know what caused gene therapy death
Capsida Biotherapeutics said Tuesday that it still had no answers in its investigation into the death of a child in a gene therapy trial last September....
-
Uncategorized1 month ago
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
-
Uncategorized1 month ago
FDA turns to old drugs to address new diseases, persistent medical needs
The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.
-
Uncategorized1 month ago
Scientists say this algae could remove microplastics from drinking water
Researchers created a special kind of algae that can grab microscopic plastic pollution out of water almost like a magnet. The algae produce limonene, an orange-scented...
-
Uncategorized1 month ago
A year after Vertex’s big launch, pain drug research faces a pivotal moment
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going? Read More
-
Uncategorized1 month ago
Flagship startup, Serif, says it has solved non-viral gene therapy in monkeys
BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from...
-
Uncategorized1 month agoSTAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
Five years ago, the bottom fell out of sepsis prediction software. Hundreds of hospitals had adopted an algorithm from electronic health record company Epic that promised...
-
Uncategorized1 month ago
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
-
Uncategorized1 month agoPCOS’s new name is PMOS, a small letter change that required a big scientific process
PCOS is dead. Long live PMOS. Revealed Tuesday, the one-letter change in nomenclature for a common metabolic condition in women may seem unremarkable, but it follows...
-
Uncategorized1 month agoSTAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Bristol Myers Squibb announced on Tuesday a partnership with Hengrui Pharma covering more than a dozen early-stage programs, the latest and a notably large case of...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
